OREANDA-NEWS. Bristol-Myers Squibb Company (NYSE:BMY) announced today 36 presentations, including seven oral presentations and eight poster discussions, highlighting data from studies evaluating Opdivo® (nivolumab), Yervoy® (ipilimumab), Empliciti™ (elotuzumab) and Sprycel® (dasatinib), across 13 types of cancers, will be featured at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 3-7. The data presented at this meeting builds on the Company’s understanding of the clinical profile of these agents – as monotherapy or in combination – and reinforce its commitment to addressing significant unmet patient needs in a wide range of solid tumors and blood cancers.

Jean Viallet, M.D., Global Clinical Research Lead, Oncology, Bristol-Myers Squibb, commented, “Our Immuno-Oncology research goal is centered around increasing quality long-term survival – and doing so through the use of Immuno-Oncology combination regimens. Our development program has led to the introduction of several treatment options for cancers such as metastatic melanoma, previously treated advanced lung, renal cell carcinoma, multiple myeloma, and classical Hodgkin lymphoma, and through our robust research pipeline we continue to evaluate the potential of Immuno-Oncology in additional tumor types. At this year’s ASCO, we look forward to sharing research from our ongoing clinical trials evaluating our medicines - as monotherapy or in combination - in several types of difficult-to-treat cancers.”

The key data presentations, including clinical science symposia and oral presentations, are:

  • CheckMate -012: New overall survival data evaluating the Opdivo and Yervoy combination in first-line advanced non-small cell lung cancer (Abstract #3001). Data will be presented during an oral abstract session on Saturday, June 4, 1:27 PM – 1:39 PM CDT.
  • CheckMate -032: New overall survival data from a phase 1/2 trial evaluating Opdivo as monotherapy and in combination with Yervoy in patients with advanced small cell lung cancer (Abstract #100). Data from CheckMate -032 will be presented during a Clinical Science Symposium on Saturday, June 4, 2016, 8:12 AM – 8:24 AM CDT.
  • CheckMate -067: Updated results from pivotal, phase 3 trial of Opdivo in combination with Yervoy in treatment-naive patients with advanced melanoma (Abstract #9505). Data will be presented during an oral abstract session on Monday, June 6, 2:39 PM – 2:51 PM CDT.
  • Study -010/-003: Long-term overall survival with Opdivo in previously treated patients with advanced renal cell carcinoma from phase 1 and 2 studies (Abstract #4507). Data will be presented during an oral abstract session on Sunday, June 5, 10:24 AM – 10:36 AM CDT.
  • CheckMate -141: Updated phase 3 data evaluating Opdivo versus investigator’s choice for recurrent or metastatic head and neck squamous cell carcinoma, including quality of life assessments (Abstract #6009). Data will be presented during a Clinical Science Symposium on Monday, June 6, 11:30 AM – 11:42 AM CDT.
  • CheckMate -032: First presentation of clinical results from phase 1/2 trial evaluating Opdivo in metastatic urothelial cancer in previously treated patients (Abstract #4501). Data will be presented during an oral abstract session on Sunday, June 5, 8:12 AM – 8:24 AM CDT.
  • CheckMate -142: First disclosure of clinical results of the Opdivo and Yervoy combination regimen in patients with metastatic colorectal cancer with and without high microsatellite instability (Abstract #3501). Data will be presented during an oral abstract session on Sunday, June 5, 8:12 AM – 8:24 AM CDT.